Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report)’s stock price gapped down prior to trading on Tuesday following a weaker than expected earnings announcement. The stock had previously closed at ...

Hurricane forecasters use what are called analog seasons to predict was a future season could have in store. Forecasters pay ...

With recent studies revealing the harmful and worrying health effects of microplastics, it's more important than ever to use ...

From a bag of human hands to LEGO bricks and rubber duckies, some very weird things have washed up on the world's beaches.

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025Commercial launch in the PRC of generic nintedanib for the ...

SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing ...

Earnings per share (EPS) missed analyst estimates by 71%. In the last 12 months, the only revenue segment was Gyre Pharmaceuticals contributing US$105.8m. The largest operating expense was Sales ...